Literature DB >> 15946922

Th1-orientated immunological properties of the bacterial extract OM-85-BV.

M Huber1, H Mossmann, W G Bessler.   

Abstract

The bacterial extract OM-85-BV prepared from 21 pathogenic bacterial strains is administered orally to adults and children for the treatment and prevention of recurrent infections of the respiratory tract. We analyzed in vitro and in vivo the immunomodulatory effects of the extract. The lysate acted as a non specific macrophage activator, inducing NO production as well as the translocation of transcription factor NF-kappaB into the nucleus in murine bone marrow-derived macrophages. Besides stimulating unspecifically the immune system, a bacteria-specific humoral immune response was revealed. After oral application, a trend to increase bacteria-specific IgG and IgA in serum was observed. Also a marked increase of bacteria specific IgA in saliva as well as in supernatants of Peyer's patches and mesenteric lymph nodes-derived cell cultures was found. The immunomodulatory properties of the extract were also investigated with respect to shifting the Th1/Th2 bias in an in vivo allergy model. BALB/c mice were orally immunized with OM-85-BV and subsequently sensitized intraperitoneally with the allergen ovalbumin. The group pretreated with OM-85-BV showed a decrease of both total and ovalbumin specific IgE. Accordingly, in spleen cell supernatants the Th1-associated cytokine IFN-gamma was increased, and the Th2-associated cytokine IL-4 was downregulated. Our findings suggest that the immunoprotective effects of OM-85-BV observed in human beings may be correlated to its Th1 augmenting properties.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15946922

Source DB:  PubMed          Journal:  Eur J Med Res        ISSN: 0949-2321            Impact factor:   2.175


  20 in total

1.  OM85-BV induced the productions of IL-1β, IL-6, and TNF-α via TLR4- and TLR2-mediated ERK1/2/NF-κB pathway in RAW264.7 cells.

Authors:  Hong Luan; Qian Zhang; Le Wang; Chuanxiao Wang; Miao Zhang; Xiaoli Xu; Huan Zhou; Xing'ai Li; Qing Xu; Fan He; Jin Yuan; Yongman Lv
Journal:  J Interferon Cytokine Res       Date:  2014-03-07       Impact factor: 2.607

Review 2.  Bringing Stability to the Chronic Obstructive Pulmonary Disease Patient: Clinical and Pharmacological Considerations for Frequent Exacerbators.

Authors:  Swati Gulati; J Michael Wells
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

3.  Sublingual therapeutic immunization with a polyvalent bacterial preparation in patients with recurrent respiratory infections: immunomodulatory effect on antigen-specific memory CD4+ T cells and impact on clinical outcome.

Authors:  D Alecsandru; L Valor; S Sánchez-Ramón; J Gil; J Carbone; J Navarro; J Rodríguez; C Rodríguez-Sainz; E Fernández-Cruz
Journal:  Clin Exp Immunol       Date:  2011-04       Impact factor: 4.330

4.  Emerging Therapies in the Treatment of Early Childhood Wheeze.

Authors:  Elissa M Abrams; Hengameh H Raissy
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2019-06-17       Impact factor: 1.349

5.  Enhanced Mucosal Antibody Production and Protection against Respiratory Infections Following an Orally Administered Bacterial Extract.

Authors:  Christian Pasquali; Olawale Salami; Manisha Taneja; Eva S Gollwitzer; Aurelien Trompette; Céline Pattaroni; Koshika Yadava; Jacques Bauer; Benjamin J Marsland
Journal:  Front Med (Lausanne)       Date:  2014-10-30

6.  Broncho Vaxom (OM-85) modulates rhinovirus docking proteins on human airway epithelial cells via Erk1/2 mitogen activated protein kinase and cAMP.

Authors:  Michael Roth; Christian Pasquali; Daiana Stolz; Michael Tamm
Journal:  PLoS One       Date:  2017-11-28       Impact factor: 3.240

7.  OM-85 is an immunomodulator of interferon-β production and inflammasome activity.

Authors:  A T Dang; C Pasquali; K Ludigs; G Guarda
Journal:  Sci Rep       Date:  2017-03-06       Impact factor: 4.379

8.  Evidence that a primary anti-viral stimulation of the immune response by OM-85 reduces susceptibility to a secondary respiratory bacterial infection in mice.

Authors:  Giovanni A Rossi; Wolfgang Bessler; Stefania Ballarini; Christian Pasquali
Journal:  Ital J Pediatr       Date:  2018-09-26       Impact factor: 2.638

9.  Use of the Bacterial Lysate OM-85 in the Paediatric Population in Italy: A Retrospective Cohort Study.

Authors:  Anna Cantarutti; Elisa Barbieri; Antonio Scamarcia; Luigi Cantarutti; Cristina Canova; Carlo Giaquinto
Journal:  Int J Environ Res Public Health       Date:  2021-06-26       Impact factor: 3.390

10.  Prevention of respiratory tract infections with bacterial lysate OM-85 bronchomunal in children and adults: a state of the art.

Authors:  Fernando De Benedetto; Gianfranco Sevieri
Journal:  Multidiscip Respir Med       Date:  2013-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.